Results 61 to 70 of about 37,260 (216)
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Arthritis &Rheumatology, EarlyView.Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source
IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis
Arthritis &Rheumatology, EarlyView.Objective Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. IgG from patients with LN displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay +3 more
wiley +1 more source
The Dual Role of Microbiota as a Therapeutic Target in Lupus Nephritis
Turkish Journal of NephrologyLupus nephritis, a severe manifestation of systemic lupus erythematosus (SLE), involves kidney inflammation driven by immune dysregulation. Emerging evidence highlights gut microbiota as a key factor in lupus nephritis pathogenesis, with dysbiosis ...
Ramesa Shafi Bhat
doaj +1 more source
Arthritis &Rheumatology, Accepted Article.Objective Systemic lupus erythematosus (SLE) is characterized by type I interferon (IFN) signaling and adaptive immune dysregulation. We previously identified hypomethylation of HLA‐DRB1 and STAT1 in SLE CD8+ T cells, enabling aberrant IFN‐driven HLA‐DRB1 expression and expansion of a distinct CD8+ T cell subset. This study characterized CD8+ HLA‐DRB1+
Huizhong Long +3 more
wiley +1 more source
Indonesian Journal of Rheumatology, 2018 Background : Systemic lupus erythematosus (SLE) is a systemic autoimmune disease involving multiple organs including kidney and known as lupus nephritis (LN). Lupus nephritis has a poor prognosis after a 10-years onset, more than 25% will be ended by end
Y H Aini +3 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
The Clinicopathological Study of Lupus Nephritis
Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2014 Purpose: Lupus nephritis is one of the most serious manifestations of Systemic lupus erythematosis and it is a major cause of morbidity and mortality. The aim of this study is to compare males and females in lupus nephritis presentations.
Raouf Rahim Merza +2 more
doaj
Successful Management Strategies for Lupus Nephritis in the Intensive Care Unit: A Case Series
Archives of Anesthesia and Critical CareLupus nephritis, a severe complication of systemic lupus erythematosus (SLE), often leads to significant renal impairment requiring intensive care. The management of lupus nephritis in the intensive care unit of Dr.
Achmad Marwan +2 more
doaj +1 more source
Revista Colombiana de Nefrología, 2014 Lupus nephritis is one of the most severe manifestations of systemic lupus erythematous. Renal involvement in patients with systemic lupus erythematous is an important cause of morbidity and mortality. The pathogenesis of lupus nephritis involve multiple
Lisandro Pacheco-Lugo +2 more
doaj +1 more source